about
[Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study].Epidemiology of hidradenitis suppurativa and inflammatory bowel disease: are these two disease associated?Management of patients with hidradenitis suppurativa.Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.Management of the Psychological Impact of Inflammatory Bowel Disease: Perspective of Doctors and Patients-The ENMENTE Project.Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.The psychosocial impact of inflammatory bowel disease and its management. From the patients' perspective.Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.Response to Gracie and Ford.Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.Therapeutic approach to Crohn disease: possible parallels with hidradenitis suppurativa.Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study).Retrograde single-balloon enteroscopy for the removal of a mollusc shell retained in the ileum of a patient with active Crohn's diseaseHealthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC ScaleRecomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad de Crohn y Colitis Ulcerosa (ACCU) para el manejo de los aspectos psicológicos en la enfermedad inErratum: Corrigendum: Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC StudyAssociation between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC studyQuality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trialPrevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre StudyImpact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study[COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)]EditorialSerial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
P50
Q35966938-97580DF4-985F-459D-BA1D-D80ED1C4376EQ39024098-FCAD84F2-EE59-4A83-AD8F-E5E5BA090017Q39084198-71F5ED92-EDDD-4DED-B68B-955A2429A231Q40282145-ADCC5980-2003-49F3-A7F3-8A3575AF6E49Q47803443-7DAA5DFA-976A-4949-9C1C-A64B52BDA437Q48788924-9C084613-20BD-4B39-9F78-45BE07F9E7B1Q48904882-DA98800C-C274-4AF2-A3F8-B033350554A2Q49818443-75B62C4B-007B-4380-B0BF-1C85141B5A5AQ50108545-045E18A6-DBB5-4AB8-A972-0D16B477F98BQ50237402-490394A0-A09F-4FA4-8C32-84340D871C33Q50238623-02D0B331-58E0-4090-B3BE-8B72A0E10EB8Q51195004-F80E9D18-3E9F-4E12-B979-4CAAEC140D14Q51195023-B8F37C42-3772-4294-A881-5E306FA1105CQ52657110-A74835FE-E6E4-4D99-AFBB-4A4C5CFB2F8BQ58594677-854F3CD9-B4F4-41DE-B562-7FDF1AFA8EA2Q59350947-873EC4FA-5DF5-4CCA-9059-780E607F221DQ61349523-AD9BA196-AD84-4DD1-BAF0-E4E4A72BB5F9Q61962899-F33ABAD0-F36C-4FB3-9A96-B893D7F233E4Q87734297-5A1D49A4-0048-40BA-BED9-2197C1EA29A8Q91321922-A0D96C14-5AE8-4D6F-8802-15A24F793103Q91355368-0741A133-5D11-4AF5-A637-99DFE2137A91Q93240261-7065A776-E7CC-4D00-B867-7F2CE21CE64AQ94959537-DDBDDC60-763E-494E-B883-8A1C40742603Q95439263-0FA5FBAD-5DDF-4E49-BFE2-0CD4A0FECD21Q95725587-1D5E4F28-B05A-4364-88DB-FC9296E1F27E
P50
description
investigador
@es
researcher
@en
name
Ignacio Marín-Jiménez
@en
type
label
Ignacio Marín-Jiménez
@en
prefLabel
Ignacio Marín-Jiménez
@en
P31
P496
0000-0001-5424-2484